Linagliptin Krka (Linagliptin)

Linagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition prevents the breakdown of incretin hormones such as GLP‑1 and GIP, which in turn increases insulin secretion in response to meals and reduces glucagon release, leading to improved glycemic control.

The appropriate dose of Linagliptin Krka is determined by the prescribing healthcare professional based on the individual patient's clinical condition, renal function and concomitant therapies. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose without medical advice.

The safety of linagliptin in pregnancy and lactation has not been definitively established. It should only be used during pregnancy or while breastfeeding if the potential benefits outweigh the possible risks, and this decision must be made by a qualified healthcare provider.

To order Linagliptin Krka, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin shares the same mechanism of DPP‑4 inhibition as other agents in its class, but it is distinguished by its high binding affinity and minimal renal excretion, allowing use without dose adjustment in most patients with renal impairment. Compared with sulfonylureas, it carries a lower risk of hypoglycaemia and does not require routine blood‑sugar monitoring.

Linagliptin Krka tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Linagliptin Krka is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional and should not crush or chew the tablet.

Serious adverse events linked to Linagliptin include pancreatitis, severe hypersensitivity reactions such as angioedema or anaphylaxis, and significant elevations in liver enzymes. Patients should seek immediate medical attention if they experience persistent abdominal pain, signs of an allergic reaction, or jaundice.

Linagliptin Krka is contraindicated in patients with a known hypersensitivity to linagliptin or any of the tablet's excipients. Caution is also advised for individuals with a history of pancreatitis, severe hepatic impairment, or those taking medications that may cause major drug interactions, unless closely monitored by a physician.